Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Mirati Therapeutics Was Sinking This Week

TheMotleyFool

0 0

Why Mirati Therapeutics Was Sinking This WeekPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Shares of oncology-focused biotech Mirati Therapeutics (NASDAQ: MRTX) have stumbled across the past few days, with the stock trading in the red by nearly 11% week to date as of Thursday's close. A spot of good news from a product that rivals its key pipeline drug seemed to be the force pulling down Mirati's shares.

On Monday, Mirati's large and powerful peer Amgen (NASDAQ: AMGN) announced it had received conditional marketing authorization from the European Commission for its drug Lumykras to treat advanced non-small cell lung cancer (NSCLC) with the KRAS G12C (a protein) mutation in adults.

Image source: Getty Images.

Source Fool.com

Like: 0

MRTX

Teilen